Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BDKRB1 | P46663 | 11/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | TAOK1 | Q7L7X3 | 1/20 | 0.40 |
| ▸ | TAOK3 | Q9H2K8 | 1/20 | 0.40 |
| ▸ | CTSS | P25774 | 1/20 | 0.40 |
| ▸ | CFD | P00746 | 2/20 | 0.39 |
| ▸ | PRSS12 | P56730 | 2/20 | 0.39 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.38 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.38 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.38 |
| ▸ | TAS1R2 | Q8TE23 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL46854 | 1.00 | BDKRB1 (0.43) | BDKRB1LMNAPOLBTAOK1TAOK3 | |
| SCHEMBL46853 | 0.95 | BDKRB1 (0.41) | BDKRB1LMNAPOLBTAOK1TAOK3 | |
| SCHEMBL46852 | 0.94 | BDKRB1 (0.41) | BDKRB1LMNAPOLBTAOK1TAOK3 | |
| SCHEMBL15432810 | 0.94 | BDKRB1 (0.41) | BDKRB1LMNAPOLBTAOK1TAOK3 | |
| SCHEMBL16355234 | 0.90 | BDKRB1 (0.39) | BDKRB1LMNAPOLBTAOK1TAOK3 | |
| SCHEMBL19596363 | 0.90 | BDKRB1 (0.39) | BDKRB1LMNAPOLBTAOK1TAOK3 | |
| SCHEMBL16804646 | 0.90 | BDKRB1 (0.38) | BDKRB1LMNAPOLBTAOK1TAOK3 | |
| SCHEMBL15432811 | 0.90 | BDKRB1 (0.38) | BDKRB1LMNAPOLBTAOK1TAOK3 | |
| SCHEMBL16355235 | 0.86 | BDKRB1 (0.35) | BDKRB1LMNAPOLBTAOK1TAOK3 | |
| SCHEMBL15421196 | 0.86 | BDKRB1 (0.35) | BDKRB1LMNAPOLBTAOK1TAOK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170037010-A1 | COMPOUNDS AND METHODS FOR INHIBITING PHOSPHATE TRANSPORT | ARDELYX, INC. | 2017-02-09 | — | — | US | disclosed |
| US-20170037010-A1 | COMPOUNDS AND METHODS FOR INHIBITING PHOSPHATE TRANSPORT | ARDELYX, INC. | 2017-02-09 | — | — | US | disclosed |
| US-8916569-B2 | Compounds and methods for inhibiting phosphate transport | ARDELYX, INC. (US) | 2014-12-23 | — | — | US | disclosed |
| US-20140023611-A1 | COMPOUNDS AND METHODS FOR INHIBITING PHOSPHATE TRANSPORT | ARDELYX, INC. | 2014-01-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170037010-A1 | COMPOUNDS AND METHODS FOR INHIBITING PHOSPHATE TRANSPORT | SLC34A2, SLC34A1, SLC10A2 | BDKRB1 920/4885LMNA 2948/4885POLB 2222/4885 |
| US-20140023611-A1 | COMPOUNDS AND METHODS FOR INHIBITING PHOSPHATE TRANSPORT | SLC10A2, SLC34A2, SLC34A3 | BDKRB1 1954/4885LMNA 3817/4885POLB 1451/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.